A subgroup analysis completed according to region, age, time from diagnosis of metastatic colorectal cancer to randomization, prior lines of treatment, and KRAS status revealed no significant differences in OS or PFS outcomes (Grothey et al., 2012; Van Cutsem et al., 2012). The gene discussed is KRAS; the disease is metastatic colorectal cancer.